Catiolanze (latanoprost)
- Region
- 🇪🇺 EU
- Active substance
- latanoprost
- Company
- Santen Oy
- Status
- Authorised
- Therapeutic area
- Glaucoma, Open-Angle
- CHMP opinion
- Thu 14 Sep 2023
- EU approval
- Wed 15 Nov 2023
- Application
- EMEA/H/C/005933
- ATC
- S01EE01
- Official record
- www.ema.europa.eu
Indication
Catiolanze is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with open angle glaucoma or ocular hypertension. Catiolanze is indicated for the reduction of elevated IOP in children from 4 years of age and adolescents with elevated IOP and paediatric glaucoma.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Roclanda Authorised · Santen Oy
Follow Catiolanze
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.